Cornerstone reference
By Joe, founder · Updated 29 April 2026 · ~12 min read
A free, single-page reference manual for 50+ research peptides A to Z. Each entry has sequence, half-life, mechanism, stability profile and a primary literature citation. Maintained by us, no signup, no paywall.
Trust signals, supplier vetting, what actually goes wrong. The honest writing the rest of the market avoids.
Building the technical fluency to evaluate any supplier yourself.
Single-peptide writing, drawn from the published literature.
Compound deep-dive
TB-500: the Thymosin Beta-4 fragment
By Joe · 12 May 2026 · ~10 min read
A synthetic peptide built around the conserved LKKTET actin-binding motif of Thymosin Beta-4. Forty years of Goldstein and Kleinman literature. And the fragment-versus-full-protein chemistry question that most suppliers leave fuzzy.
Compound deep-dive
Semaglutide: the GLP-1 receptor agonist that defined the modern era
By Joe · 10 May 2026 · ~10 min read
A 31-amino-acid molecule from Novo Nordisk. Three small modifications to native GLP-1 produced an 11000-fold half-life jump. STEP-1 (14.9 percent body-weight reduction at 68 weeks) and SELECT (20 percent MACE reduction in non-diabetic CVD adults). The benchmark every later compound is measured against.
Compound deep-dive
Retatrutide: the triple-receptor agonist
By Joe · 6 May 2026 · ~10 min read
A 39-amino-acid synthetic peptide developed by Eli Lilly that activates three receptors at once: GIP, GLP-1, and glucagon. The first trinity agonist to publish a full Phase 2 dataset (Jastreboff NEJM 2023). 24.2 percent body-weight reduction at 48 weeks. TRIUMPH Phase 3 in progress.
Compound deep-dive
Tirzepatide: the dual GIP and GLP-1 receptor agonist
By Joe · 6 May 2026 · ~10 min read
A 39-amino-acid synthetic peptide developed by Eli Lilly that simultaneously activates both incretin receptors. The first twincretin to reach late-stage development. Beat semaglutide on every endpoint of SURPASS-2. Sits as the most-discussed compound in metabolic research right now, and the most actively counterfeited.
Compound deep-dive
BPC-157: the most-researched peptide in the catalogue
By Joe · 6 May 2026 · ~9 min read
A 15-amino-acid fragment derived from a body-protective compound first isolated from human gastric juice. Characterised at the University of Zagreb from 1991 onwards. Over 200 peer-reviewed papers. The unusual property that put it on the map: it survives gastric acid.
Compound deep-dive
Selank: the underrated Russian anxiolytic peptide
By Joe · 2 May 2026 · ~9 min read
A synthetic tuftsin analogue developed at the Russian Academy of Medical Sciences in the 1990s. Thirty years of literature on tuftsin-family receptor binding, GABAergic modulation, BDNF effects and the intranasal route - almost completely absent from Western research conversations.
Compound deep-dive
GHK-Cu explained: the blue copper peptide
By Joe · 1 May 2026 · ~8 min read
The copper-bound tripeptide first isolated by Pickart in 1973. Why it's vivid cobalt blue, what 50 years of literature says, how to verify a batch is real, and the supplier red flags almost no buyer knows to check.
Compound deep-dive
Semaglutide vs Retatrutide: single vs triple receptor agonist
Updated 26 April 2026 · ~6 min read
Side-by-side comparison of the two most-cited GLP-1-class compounds in current metabolic-research literature. Receptor pharmacology, half-life, lab handling.
Compound deep-dive
GHK-Cu vs BPC-157: copper tripeptide vs pentadecapeptide
Updated 26 April 2026 · ~5 min read
Two of the most widely cited regenerative-research peptides with very different chemistry. Mechanism, stability, selection criteria.
Compound deep-dive
CJC-1295 (DAC) vs Sermorelin: extended vs original GHRH
Updated 26 April 2026 · ~5 min read
Both are GHRH receptor agonists, but they differ dramatically in serum half-life. Why DAC modification changes everything.
MHRA framework, Misuse of Drugs Act position, customs reality.
New post about once a month
No marketing spam. Just a note when something material gets added or updated.
One email per new post, ~monthly cadence. Unsubscribe in one click. We never share or sell email addresses.
Thanks — you're subscribed. We'll email you when something material gets added.